Enhanced levels of urokinase plasminogen activator and its soluble receptor in common variable immunodeficiency

Clinical Immunology

Volumn 131, Issue 3, 2009, Pages 438-446

  Fevang, Børre ^a   Eugen Olsen, Jesper ^b   Yndestad, Arne ^a   Brosstad, Frank ^a   Beiske, Klaus ^c   Aukrust, Pål ^a,c   Frøland, Stig S ^a,c  

^a UNIVERSITY OF OSLO   (Norway)

^b Mental Health Services CPH   (Denmark)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Chronic inflammation; CVID; suPAR; uPA; uPAR

Indexed keywords

BIOLOGICAL MARKER; CD14 ANTIGEN; CD3 ANTIGEN; NEOPTERIN; UROKINASE; UROKINASE RECEPTOR;

ADULT; ARTICLE; BLOOD LEVEL; CELL ACTIVATION; CHRONIC INFLAMMATION; CLINICAL FEATURE; COMMON VARIABLE IMMUNODEFICIENCY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GRANULOMATOSIS; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLENOMEGALY; THROMBOCYTOPENIA;

ADULT; COMMON VARIABLE IMMUNODEFICIENCY; FEMALE; HUMANS; MALE; MIDDLE AGED; MONOCYTES; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 67349094601     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.01.007     Document Type: Article

References (47)

1. Rosen F.S., Eibl M.M., Roifman C.M., Fischer A., Volanakis J., Aitui F., Notarangelo L., Kishimoto T., Resnick I.B., Hammarstrom L., Seger R., Chapel H., Cooper M.D., Geha R.S., Good R.A., Waldmann T.A., and Wedgwood R.J. Primary immunodeficiency diseases. Report of an IUIS Scientific Committee. International Union of Immunological Societies. Clin. Exp. Immunol. 118 Suppl 1 (1999) 1-28
2. Brandt D., and Gershwin M.E. Common variable immune deficiency and autoimmunity. Autoimmune Rev. 5 (2006) 465-470
3. Di Renzo M., Pasqui A.L., and Auteri A. Common variable immunodeficiency: a review. Clin. Exp. Med. 3 (2004) 211-217
4. Mondino A., and Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol. 25 (2004) 450-455
5. Heymans S., Pauschinger M., De P.A., Kallwellis-Opara A., Rutschow S., Swinnen M., Vanhoutte D., Gao F., Torpai R., Baker A.H., Padalko E., Neyts J., Schultheiss H.P., Van de W.F., Carmeliet P., and Pinto Y.M. Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis. Circulation 114 (2006) 565-573
6. Gyetko M.R., Chen G.H., McDonald R.A., Goodman R., Huffnagle G.B., Wilkinson C.C., Fuller J.A., and Toews G.B. Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model. J. Clin. Invest. 97 (1996) 1818-1826
7. Gyetko M.R., Sud S., Chen G.H., Fuller J.A., Chensue S.W., and Toews G.B. Urokinase-type plasminogen activator is required for the generation of a type 1 immune response to pulmonary Cryptococcus neoformans infection. J. Immunol. 168 (2002) 801-809
8. Shapiro R.L., Duquette J.G., Nunes I., Roses D.F., Harris M.N., Wilson E.L., and Rifkin D.B. Urokinase-type plasminogen activator-deficient mice are predisposed to staphylococcal botryomycosis, pleuritis, and effacement of lymphoid follicles. Am. J. Pathol. 150 (1997) 359-369
9. Beck J.M., Preston A.M., and Gyetko M.R. Urokinase-type plasminogen activator in inflammatory cell recruitment and host defense against Pneumocystis carinii in mice. Infect. Immun. 67 (1999) 879-884
10. Min H.Y., Doyle L.V., Vitt C.R., Zandonella C.L., Stratton-Thomas J.R., Shuman M.A., and Rosenberg S. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. 56 (1996) 2428-2433
11. Busso N., Peclat V., So A., and Sappino A.P. Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints. Ann. Rheum. Dis. 56 (1997) 550-557
12. Krasnikova T.L., Parfyonova Y., Alekseeva I.A., Arefieva T.I., Mukhina S.A., Dobrovolsky A.B., Titaeva Y., Lyakishev A.A., Resink T.J., Erne P., and Tkachuk V.A. Urokinase plasminogen activator system in humans with stable coronary artery disease. Clin. Exp. Pharmacol. Physiol. 26 (1999) 354-357
13. Brooks A.M., Bates M.E., Vrtis R.F., Jarjour N.N., Bertics P.J., and Sedgwick J.B. Urokinase-type plasminogen activator modulates airway eosinophil adhesion in asthma. Am. J. Respir. Cell Mol. Biol. 35 (2006) 503-511
14. Montuori N., Visconte V., Rossi G., and Ragno P. Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules?. Thromb. Haemost. 93 (2005) 192-198
15. Fazioli F., Resnati M., Sidenius N., Higashimoto Y., Appella E., and Blasi F. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. 16 (1997) 7279-7286
16. Gyetko M.R., Sud S., Kendall T., Fuller J.A., Newstead M.W., and Standiford T.J. Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection. J. Immunol. 165 (2000) 1513-1519
17. Rijneveld A.W., Levi M., Florquin S., Speelman P., Carmeliet P., and van der P.T. Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J. Immunol. 168 (2002) 3507-3511
18. de Bock C.E., and Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med. Res. Rev. 24 (2004) 13-39
19. Slot O., Brunner N., Locht H., Oxholm P., and Stephens R.W. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 58 (1999) 488-492
20. Chu S.C., Yang S.F., Lue K.H., Hsieh Y.S., Hsiao T.Y., and Lu K.H. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee. J. Rheumatol. 33 (2006) 311-317
21. Eugen-Olsen J., Gustafson P., Sidenius N., Fischer T.K., Parner J., Aaby P., Gomes V.F., and Lisse I. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int. J. Tuberc. Lung Dis. 6 (2002) 686-692
22. Wittenhagen P., Kronborg G., Weis N., Nielsen H., Obel N., Pedersen S.S., and Eugen-Olsen J. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality. Clin. Microbiol. Infect. 10 (2004) 409-415
23. Ostergaard C., Benfield T., Lundgren J.D., and Eugen-Olsen J. Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Scand. J. Infect. Dis. 36 (2004) 14-19
24. Sidenius N., Sier C.F., Ullum H., Pedersen B.K., Lepri A.C., Blasi F., and Eugen-Olsen J. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 96 (2000) 4091-4095
25. Ostrowski S.R., Katzenstein T.L., Pedersen M., Hoyer-Hansen G., Gerstoft J., Pedersen B.K., and Ullum H. Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy. Scand. J. Immunol. 63 (2006) 478-486
26. Aukrust P., Froland S.S., and Muller F. Raised serum neopterin levels in patients with primary hypogammaglobulinaemia; correlation to other immunological parameters and to clinical and histological features. Clin. Exp. Immunol. 89 (1992) 211-216
27. Fevang B., Mollnes T.E., Holm A.M., Ueland T., Heggelund L., Damas J.K., Aukrust P., and Froland S.S. Common variable immunodeficiency and the complement system; low mannose-binding lectin levels are associated with bronchiectasis. Clin. Exp. Immunol. 142 (2005) 576-584
28. Schaffer A.A., Salzer U., Hammarstrom L., and Grimbacher B. Deconstructing common variable immunodeficiency by genetic analysis. Curr. Opin. Genet. Dev. 17 (2007) 201-212
29. Bollerslev J., Ueland T., Jorgensen A.P., Fougner K.J., Wergeland R., Schreiner T., and Burman P. Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency. Eur. J. Endocrinol. 154 (2006) 537-543
30. Aukrust P., Aandahl E.M., Skalhegg B.S., Nordoy I., Hansson V., Tasken K., Froland S.S., and Muller F. Increased activation of protein kinase A type I contributes to the T cell deficiency in common variable immunodeficiency. J. Immunol. 162 (1999) 1178-1185
31. Stylianou E., Aukrust P., Muller F., Nordoy I., and Froland S.S. Complex effects of interferon-alpha on the cytokine network in HIV infection-possible contribution to immunosuppression. Cytokine 14 (2001) 56-62
32. Hansen J.B., Halvorsen D.S., Haldorsen B.C., Olsen R., Sjursen H., and Kierulf P. Retention of phagocytic functions in cryopreserved human monocytes. J. Leukoc. Biol. 57 (1995) 235-241
33. Wehr C., Kivioja T., Schmitt C., Ferry B., Witte T., Eren E., Vlkova M., Hernandez M., Detkova D., Bos P.R., Poerksen G., von B.H., Baumann U., Goldacker S., Gutenberger S., Schlesier M., Bergeron-van der C.F., Le G.M., Debre P., Jacobs R., Jones J., Bateman E., Litzman J., van Hagen P.M., Plebani A., Schmidt R.E., Thon V., Quinti I., Espanol T., Webster A.D., Chapel H., Vihinen M., Oksenhendler E., Peter H.H., and Warnatz K. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood 111 (2008) 77-85
34. Jaffar S., Van der Loeff M.S., Eugen-Olsen J., Vincent T., Sarje-Njie R., Ngom P., Meyer A.M., Berry N., Aaby P., and Whittle H. Immunological predictors of survival in HIV type 2-infected rural villagers in Guinea-Bissau. AIDS Res. Hum. Retrovir. 21 (2005) 560-564
35. Moller H.J., Moestrup S.K., Weis N., Wejse C., Nielsen H., Pedersen S.S., Attermann J., Nexo E., and Kronborg G. Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163. Crit. Care Med. 34 (2006) 2561-2566
36. Ostrowski S.R., Plomgaard P., Fischer C.P., Steensberg A.S., Moller K., Hoyer-Hansen G., Pedersen B.K., and Ullum H. Interleukin-6 infusion during human endotoxaemia inhibits in vitro release of the urokinase receptor from peripheral blood mononuclear cells. Scand. J. Immunol. 61 (2005) 197-206
37. Dekkers P.E., ten H.T., te Velde A.A., van Deventer S.J., and van der P.T. Upregulation of monocyte urokinase plasminogen activator receptor during human endotoxemia. Infect. Immun. 68 (2000) 2156-2160
38. Chavakis T., Kanse S.M., Yutzy B., Lijnen H.R., and Preissner K.T. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood 91 (1998) 2305-2312
39. Nykjaer A., Moller B., Todd III R.F., Christensen T., Andreasen P.A., Gliemann J., and Petersen C.M. Urokinase receptor. An activation antigen in human T lymphocytes. J. Immunol. 152 (1994) 505-516
40. Florquin S., van den Berg J.G., Olszyna D.P., Claessen N., Opal S.M., Weening J.J., and van der P.T. Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. Kidney Int. 59 (2001) 2054-2061
41. Pawlak K., Mysliwiec M., and Pawlak D. The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients. Thromb. Res. (2007)
42. Aukrust P., Muller F., and Froland S.S. Elevated serum levels of interleukin-4 and interleukin-6 in patients with common variable immunodeficiency (CVI) are associated with chronic immune activation and low numbers of CD4+ lymphocytes. Clin. Immunol. Immunopathol. 70 (1994) 217-224
43. Aukrust P., Lien E., Kristoffersen A.K., Muller F., Haug C.J., Espevik T., and Froland S.S. Persistent activation of the tumor necrosis factor system in a subgroup of patients with common variable immunodeficiency-possible immunologic and clinical consequences. Blood 87 (1996) 674-681
44. Leib S.L., and Tauber M.G. Pathogenesis of bacterial meningitis. Infect. Dis. Clin. North Am. 13 (1999) 527-5vi
45. Cao D., Mizukami I.F., Garni-Wagner B.A., Kindzelskii A.L., Todd III R.F., Boxer L.A., and Petty H.R. Human urokinase-type plasminogen activator primes neutrophils for superoxide anion release. Possible roles of complement receptor type 3 and calcium. J. Immunol. 154 (1995) 1817-1829
46. Gyetko M.R., Aizenberg D., and Mayo-Bond L. Urokinase-deficient and urokinase receptor-deficient mice have impaired neutrophil antimicrobial activation in vitro. J. Leukoc. Biol. 76 (2004) 648-656
47. Jin T., Bokarewa M., and Tarkowski A. Urokinase-type plasminogen activator, an endogenous antibiotic. J. Infect. Dis. 192 (2005) 429-437